Beacon Medical Interchange is a venture founded in 2016 by Dr. Jack West to facilitate communication of medical experts with industry leaders on the evolution of medical care trends in general and cancer management in particular.
Focusing on issues ranging from behavioral economics and decision-making based on emerging data to trends such as telemedicine, social media, and the growing role of algorithm-based interventions, Dr. West facilitates data collection and moderates interactive meetings, advisory boards, producing summary reports of current and projected market analysis.
To discuss potential new programs or sponsorship/participation in current ones, please contact Dr. West.
Recent Beacon Media Posts
Dr. Jack West assesses the merits of a combination of chemotherapy with pembrolizumab (Keytruda) based on the evolving efficacy data, especially the maturing results for overall survival, with longer follow-up of the KEYNOTE-021g trial. (6:55)
Dr. Jack West reviews the important, clinically relevant results of the CheckMate-153 trial that asks whether there is a value in continuing an immune checkpoint inhibitor in patients with advanced NSCLC doing well on immunotherapy. (7:00)
Dr. Jack West reviews data from ESMO 2017 & the NEJM paper on the PACIFIC trial of durvalumab vs. placebo as consolidation after chemoradiation for patients with unresectable stage III NSCLC, focusing especially on why these results are practice-changing. (9:36)